speb/financial-data huggingface dataset:
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 30112000.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Operating Income: 48229000.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 486680000.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 349000.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 50597000.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 41547000.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 305188000.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 12012000.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 11435000.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.28
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 438451000.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 0.00
IRISDOREME.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — +Operating Expense: 526930000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 166160000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — +Total Revenue: 1908694000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 604785000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 246811000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 246811000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 722932000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 722932000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 189217647.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 0.34
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 760000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -167730000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 142517000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 142517000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 380663000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 380663000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 1775000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 1775000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 10733000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 10733000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -63069000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Change In Payable: 35992000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -280265000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -307342000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 1014000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Common Stock: 380663000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 380663000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 1417593000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 1417593000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 475829000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 69902000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 69902000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 1137060000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 343294000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Current Assets: 1591260000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 1591260000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 22075000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 22075000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Current Debt: 200614000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 200614000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 222689000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 222689000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 499195000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 499195000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Depreciation: 46607000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 46607000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 46608000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 12747000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 46608000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 12747000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 189217647.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.34
IRISDOREME.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 161924000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 64334000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — EBIT: 247780000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — EBIT: 97618000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — EBITDA: 294388000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — EBITDA: 110365000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — End Cash Position: 1775000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 235614000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -234772000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 932000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 932000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 398496000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 398496000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Gross Profit: 771634000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 261491000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Interest Expense: 26678000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 8935000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 26678000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 8935000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -26678000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 687000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Inventory: 760125000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 760125000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 1618207000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 1618207000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -167558000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 475829000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 120442000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 120442000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 120442000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 120442000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 475829000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Net Debt: 198839000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 198839000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Net Income: 161924000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Net Income: 64334000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 161924000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 64334000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 161924000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 64334000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 161924000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 64334000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 161924000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 64334000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 221102000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 161924000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 64334000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Net Interest Income: -26678000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -8935000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -515000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -174546000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -26678000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -8935000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Net PPE: 398496000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 398496000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -167730000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: -174546000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 1416661000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 1416661000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 11579000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 11579000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 294388000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 110365000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Normalized Income: 161924000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 64334000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: -67042000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Operating Income: 244704000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Operating Income: 95331000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Operating Revenue: 1908694000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 604785000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Other Cash Adjustment Outside Changein Cash: 1000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 100199000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 100199000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 29564000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 29564000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 1036930000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 1036930000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 932000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 932000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 25990000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: -1000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: -1000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 3074000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 2285000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 224694000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 78759000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Other Properties: 328594000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 328594000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 1107000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 1107000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 8958000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 8958000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Payables: 246811000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Payables: 246811000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Pretax Income: 221102000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 88683000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -167730000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 1137060000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 343294000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 46607000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 12747000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -174546000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Short Term Debt Payments: -174546000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Special Income Charges: 0.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 1417593000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 1417593000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 1416661000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 1416661000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Tax Provision: 59178000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 24349000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.27
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.27
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: -3836000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: -3836000.00
IRISDOREME.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -53399000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Total Assets: 2037229000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 2037229000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 1417593000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 1417593000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Total Debt: 343131000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 343131000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 1417593000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 1417593000.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Total Expenses: 1663990000.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 509454000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 619636000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 619636000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 445969000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 445969000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 120441000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 120441000.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 0.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 0.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 0.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
IRISDOREME.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
IRISDOREME.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
IRISDOREME.NS balance_sheet (annual, 2026-03-31) — Working Capital: 1092065000.00
IRISDOREME.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 1092065000.00
IRIX cash_flow (annual, 2021-12-31) — Change In Working Capital: 12563000.00
IRIX balance_sheet (annual, 2021-12-31) — Current Provisions: 100000.00
IRIX cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of PPE: 3000.00
IRIX cash_flow (annual, 2021-12-31) — Income Tax Paid Supplemental Data: 15000.00
IRIX cash_flow (annual, 2021-12-31) — Issuance Of Debt: 0.00
IRIX cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 0.00
IRIX balance_sheet (annual, 2021-12-31) — Long Term Provisions: 58000.00
IRIX cash_flow (annual, 2021-12-31) — Net Business Purchase And Sale: -5343000.00
IRIX cash_flow (annual, 2021-12-31) — Net Issuance Payments Of Debt: 0.00
IRIX cash_flow (annual, 2021-12-31) — Net Long Term Debt Issuance: 0.00
IRIX balance_sheet (annual, 2021-12-31) — Non Current Accrued Expenses: 58000.00
IRIX cash_flow (annual, 2021-12-31) — Operating Gains Losses: -2494000.00
IRIX balance_sheet (annual, 2021-12-31) — Prepaid Assets: 1071000.00
IRIX cash_flow (annual, 2021-12-31) — Provisionand Write Offof Assets: 37000.00
IRIX cash_flow (annual, 2021-12-31) — Purchase Of Business: -5343000.00
IRIX cash_flow (annual, 2021-12-31) — Sale Of PPE: 0.00
IRIX income_statement (annual, 2022-12-31) — +Operating Expense: 32910000.00
IRIX income_statement (annual, 2022-12-31) — +Total Revenue: 56972000.00
IRIX balance_sheet (annual, 2022-12-31) — Accounts Payable: 3858000.00
IRIX balance_sheet (annual, 2022-12-31) — Accounts Receivable: 6229000.00
IRIX balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -13559000.00
IRIX balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 86802000.00
IRIX balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -390000.00
IRIX income_statement (annual, 2022-12-31) — Basic Average Shares: 15938000.00
IRIX income_statement (annual, 2022-12-31) — Basic EPS: -0.47
IRIX cash_flow (annual, 2022-12-31) — Beginning Cash Position: 23852000.00
IRIX cash_flow (annual, 2022-12-31) — Capital Expenditure: -286000.00
IRIX balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 1769000.00
IRIX balance_sheet (annual, 2022-12-31) — Capital Stock: 169000.00
IRIX balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 13922000.00
IRIX balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 13922000.00
IRIX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -73000.00
IRIX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -286000.00
IRIX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -9519000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Account Payable: 1086000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Accrued Expense: -653000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Inventory: -3019000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Other Current Assets: -1185000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: -1015000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Other Working Capital: 868000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Payable: 474000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -179000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -397000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Receivables: -237000.00
IRIX cash_flow (annual, 2022-12-31) — Change In Working Capital: -5164000.00
IRIX cash_flow (annual, 2022-12-31) — Changes In Account Receivables: 196000.00
IRIX cash_flow (annual, 2022-12-31) — Changes In Cash: -9878000.00
IRIX balance_sheet (annual, 2022-12-31) — Common Stock: 169000.00
IRIX balance_sheet (annual, 2022-12-31) — Common Stock Equity: 17231000.00
IRIX cash_flow (annual, 2022-12-31) — Common Stock Issuance: 0.00
IRIX income_statement (annual, 2022-12-31) — Cost Of Revenue: 31604000.00
IRIX balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 1545000.00
IRIX balance_sheet (annual, 2022-12-31) — Current Assets: 35766000.00
IRIX balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 1037000.00
IRIX balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 1037000.00
IRIX balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 3379000.00
IRIX balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 3379000.00
IRIX balance_sheet (annual, 2022-12-31) — Current Liabilities: 12453000.00
IRIX cash_flow (annual, 2022-12-31) — Depreciation: 1384000.00
IRIX cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 1384000.00
IRIX cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 1384000.00
IRIX income_statement (annual, 2022-12-31) — Diluted Average Shares: 15938000.00
IRIX income_statement (annual, 2022-12-31) — Diluted EPS: -0.47
IRIX income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -7547000.00
IRIX balance_sheet (annual, 2022-12-31) — Duefrom Related Parties Current: 3539000.00
IRIX balance_sheet (annual, 2022-12-31) — Dueto Related Parties Current: 15000.00
IRIX income_statement (annual, 2022-12-31) — EBIT: -7542000.00
IRIX income_statement (annual, 2022-12-31) — EBITDA: -6158000.00
IRIX cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -52000.00
IRIX cash_flow (annual, 2022-12-31) — End Cash Position: 13922000.00
IRIX cash_flow (annual, 2022-12-31) — Financing Cash Flow: -73000.00
IRIX balance_sheet (annual, 2022-12-31) — Finished Goods: 4468000.00
IRIX cash_flow (annual, 2022-12-31) — Free Cash Flow: -9805000.00
IRIX cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: 0.00
IRIX balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -24000.00
IRIX income_statement (annual, 2022-12-31) — General And Administrative Expense: 7557000.00
IRIX balance_sheet (annual, 2022-12-31) — Goodwill: 965000.00
IRIX balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 2942000.00
IRIX balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 6619000.00
IRIX balance_sheet (annual, 2022-12-31) — Gross PPE: 15686000.00
IRIX income_statement (annual, 2022-12-31) — Gross Profit: 25368000.00
IRIX cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 73000.00
IRIX balance_sheet (annual, 2022-12-31) — Inventory: 10608000.00
IRIX balance_sheet (annual, 2022-12-31) — Invested Capital: 17231000.00
IRIX cash_flow (annual, 2022-12-31) — Investing Cash Flow: -286000.00
IRIX cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 0.00
IRIX balance_sheet (annual, 2022-12-31) — Leases: 2494000.00
IRIX balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 732000.00
IRIX balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 732000.00
IRIX cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 0.00
IRIX cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 0.00
IRIX income_statement (annual, 2022-12-31) — Net Income: -7547000.00
IRIX income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -7547000.00
IRIX income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -7547000.00
IRIX income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -7547000.00
IRIX income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -7547000.00
IRIX cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -7547000.00
IRIX income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -7547000.00
IRIX cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -94000.00
IRIX balance_sheet (annual, 2022-12-31) — Net PPE: 2127000.00
IRIX cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -286000.00
IRIX balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 14289000.00
IRIX balance_sheet (annual, 2022-12-31) — Non Current Accrued Expenses: 106000.00
IRIX balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 11742000.00
IRIX balance_sheet (annual, 2022-12-31) — Non Current Deferred Revenue: 11742000.00
IRIX income_statement (annual, 2022-12-31) — Normalized EBITDA: -6158000.00
IRIX income_statement (annual, 2022-12-31) — Normalized Income: -7547000.00
IRIX cash_flow (annual, 2022-12-31) — Operating Cash Flow: -9519000.00
IRIX income_statement (annual, 2022-12-31) — Operating Income: -7542000.00
IRIX income_statement (annual, 2022-12-31) — Operating Revenue: 56972000.00
IRIX balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 15989662.00
IRIX balance_sheet (annual, 2022-12-31) — Other Current Assets: 1468000.00
IRIX balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -24000.00
IRIX income_statement (annual, 2022-12-31) — Other Gand A: 7557000.00
IRIX income_statement (annual, 2022-12-31) — Other Income Expense: 60000.00
IRIX balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 1977000.00
IRIX balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 1455000.00
IRIX balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 26000.00
IRIX income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: 60000.00
IRIX balance_sheet (annual, 2022-12-31) — Other Payable: 106000.00
IRIX balance_sheet (annual, 2022-12-31) — Other Properties: 13192000.00
IRIX balance_sheet (annual, 2022-12-31) — Payables: 4044000.00
IRIX balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 5589000.00
IRIX balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 2448000.00
IRIX balance_sheet (annual, 2022-12-31) — Preferred Stock: 0.00
IRIX income_statement (annual, 2022-12-31) — Pretax Income: -7482000.00
IRIX cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 21000.00
IRIX balance_sheet (annual, 2022-12-31) — Properties: 0.00
IRIX cash_flow (annual, 2022-12-31) — Provisionand Write Offof Assets: 187000.00
IRIX cash_flow (annual, 2022-12-31) — Purchase Of Business: 0.00
IRIX cash_flow (annual, 2022-12-31) — Purchase Of PPE: -286000.00
IRIX balance_sheet (annual, 2022-12-31) — Raw Materials: 5820000.00
IRIX balance_sheet (annual, 2022-12-31) — Receivables: 9768000.00
IRIX income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 31604000.00
IRIX income_statement (annual, 2022-12-31) — Reconciled Depreciation: 1384000.00
IRIX income_statement (annual, 2022-12-31) — Research And Development: 7175000.00
IRIX balance_sheet (annual, 2022-12-31) — Retained Earnings: -69716000.00
IRIX income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 18178000.00
IRIX income_statement (annual, 2022-12-31) — Selling General And Administration: 25735000.00
IRIX balance_sheet (annual, 2022-12-31) — Share Issued: 15989662.00
IRIX cash_flow (annual, 2022-12-31) — Stock Based Compensation: 1621000.00
IRIX balance_sheet (annual, 2022-12-31) — Stockholders Equity: 17231000.00
IRIX balance_sheet (annual, 2022-12-31) — Tangible Book Value: 14289000.00
IRIX income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
IRIX income_statement (annual, 2022-12-31) — Tax Provision: 65000.00
IRIX income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.21
IRIX balance_sheet (annual, 2022-12-31) — Total Assets: 42290000.00
IRIX balance_sheet (annual, 2022-12-31) — Total Capitalization: 17231000.00
IRIX balance_sheet (annual, 2022-12-31) — Total Debt: 1769000.00
IRIX balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 17231000.00
IRIX income_statement (annual, 2022-12-31) — Total Expenses: 64514000.00
IRIX balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 25059000.00
IRIX balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 6524000.00
IRIX balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 12606000.00
IRIX income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -7542000.00
IRIX balance_sheet (annual, 2022-12-31) — Total Tax Payable: 65000.00
IRIX balance_sheet (annual, 2022-12-31) — Work In Process: 320000.00
IRIX balance_sheet (annual, 2022-12-31) — Working Capital: 23313000.00
IRIX income_statement (annual, 2023-12-31) — +Operating Expense: 31814000.00
IRIX income_statement (annual, 2023-12-31) — +Total Revenue: 51869000.00
IRIX balance_sheet (annual, 2023-12-31) — Accounts Payable: 4499000.00
IRIX balance_sheet (annual, 2023-12-31) — Accounts Receivable: 6727000.00
IRIX balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -13740000.00
IRIX balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 88444000.00
IRIX balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -146000.00
IRIX income_statement (annual, 2023-12-31) — Basic Average Shares: 16128000.00
IRIX income_statement (annual, 2023-12-31) — Basic EPS: -0.59
IRIX cash_flow (annual, 2023-12-31) — Beginning Cash Position: 13922000.00
IRIX cash_flow (annual, 2023-12-31) — Capital Expenditure: -109000.00
IRIX balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 2746000.00
IRIX balance_sheet (annual, 2023-12-31) — Capital Stock: 172000.00
IRIX balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 7034000.00
IRIX balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 7034000.00
IRIX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -5000.00
IRIX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -109000.00
IRIX cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -6745000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Account Payable: 641000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Accrued Expense: -381000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Inventory: 644000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Other Current Assets: -427000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: -794000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -1723000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Payable: 854000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 473000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: 612000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Receivables: 358000.00
IRIX cash_flow (annual, 2023-12-31) — Change In Working Capital: -857000.00
IRIX cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -254000.00
IRIX cash_flow (annual, 2023-12-31) — Changes In Cash: -6859000.00
IRIX balance_sheet (annual, 2023-12-31) — Common Stock: 172000.00
IRIX balance_sheet (annual, 2023-12-31) — Common Stock Equity: 9522000.00
IRIX cash_flow (annual, 2023-12-31) — Common Stock Issuance: 0.00
IRIX income_statement (annual, 2023-12-31) — Cost Of Revenue: 30062000.00
IRIX balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 2055000.00
IRIX balance_sheet (annual, 2023-12-31) — Current Assets: 27450000.00
IRIX balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 995000.00
IRIX balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 995000.00
IRIX balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 3329000.00
IRIX balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 3329000.00
IRIX balance_sheet (annual, 2023-12-31) — Current Liabilities: 12974000.00
IRIX cash_flow (annual, 2023-12-31) — Depreciation: 2032000.00
IRIX cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 2032000.00
IRIX cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 2032000.00
IRIX income_statement (annual, 2023-12-31) — Diluted Average Shares: 16128000.00
IRIX income_statement (annual, 2023-12-31) — Diluted EPS: -0.59
IRIX income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -9570000.00
IRIX balance_sheet (annual, 2023-12-31) — Duefrom Related Parties Current: 2927000.00
IRIX balance_sheet (annual, 2023-12-31) — Dueto Related Parties Current: 228000.00
IRIX income_statement (annual, 2023-12-31) — EBIT: -10007000.00
IRIX income_statement (annual, 2023-12-31) — EBITDA: -7975000.00
IRIX cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -29000.00
IRIX cash_flow (annual, 2023-12-31) — End Cash Position: 7034000.00
IRIX cash_flow (annual, 2023-12-31) — Financing Cash Flow: -5000.00
IRIX balance_sheet (annual, 2023-12-31) — Finished Goods: 4462000.00
IRIX cash_flow (annual, 2023-12-31) — Free Cash Flow: -6854000.00
IRIX balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -52000.00
IRIX income_statement (annual, 2023-12-31) — General And Administrative Expense: 8748000.00
IRIX balance_sheet (annual, 2023-12-31) — Goodwill: 965000.00
IRIX balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 2607000.00
IRIX balance_sheet (annual, 2023-12-31) — Gross Accounts Receivable: 6873000.00
IRIX balance_sheet (annual, 2023-12-31) — Gross PPE: 16723000.00
IRIX income_statement (annual, 2023-12-31) — Gross Profit: 21807000.00
IRIX cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 53000.00
IRIX balance_sheet (annual, 2023-12-31) — Inventory: 9906000.00
IRIX balance_sheet (annual, 2023-12-31) — Invested Capital: 9522000.00
IRIX cash_flow (annual, 2023-12-31) — Investing Cash Flow: -109000.00
IRIX cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 0.00
IRIX balance_sheet (annual, 2023-12-31) — Leases: 2494000.00
IRIX balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 1751000.00
IRIX balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 1751000.00
IRIX cash_flow (annual, 2023-12-31) — Long Term Debt Payments: 0.00
IRIX cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 0.00
IRIX income_statement (annual, 2023-12-31) — Net Income: -9570000.00
IRIX income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -9570000.00
IRIX income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -9570000.00
IRIX income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -9570000.00
IRIX income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -9570000.00
IRIX cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -9570000.00
IRIX income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -9570000.00
IRIX cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: 0.00
IRIX cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: 0.00
IRIX cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -87000.00
IRIX balance_sheet (annual, 2023-12-31) — Net PPE: 2983000.00
IRIX cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -109000.00
IRIX balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 6915000.00
IRIX balance_sheet (annual, 2023-12-31) — Non Current Accrued Expenses: 138000.00
IRIX balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 10025000.00
IRIX balance_sheet (annual, 2023-12-31) — Non Current Deferred Revenue: 10025000.00
IRIX income_statement (annual, 2023-12-31) — Normalized EBITDA: -7975000.00
IRIX income_statement (annual, 2023-12-31) — Normalized Income: -9570000.00
IRIX cash_flow (annual, 2023-12-31) — Operating Cash Flow: -6745000.00
IRIX income_statement (annual, 2023-12-31) — Operating Income: -10007000.00
IRIX income_statement (annual, 2023-12-31) — Operating Revenue: 51869000.00
IRIX balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 16252813.00
IRIX balance_sheet (annual, 2023-12-31) — Other Current Assets: 856000.00
IRIX balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -52000.00
IRIX income_statement (annual, 2023-12-31) — Other Gand A: 8748000.00
IRIX income_statement (annual, 2023-12-31) — Other Income Expense: 527000.00
IRIX balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 1642000.00
IRIX balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 1396000.00
IRIX balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 164000.00
IRIX income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 527000.00
IRIX balance_sheet (annual, 2023-12-31) — Other Payable: 149000.00
IRIX balance_sheet (annual, 2023-12-31) — Other Properties: 14229000.00
IRIX balance_sheet (annual, 2023-12-31) — Payables: 4976000.00
IRIX balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 7031000.00
IRIX balance_sheet (annual, 2023-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 1619000.00
IRIX balance_sheet (annual, 2023-12-31) — Preferred Stock: 0.00
IRIX income_statement (annual, 2023-12-31) — Pretax Income: -9480000.00
IRIX cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 82000.00
IRIX balance_sheet (annual, 2023-12-31) — Properties: 0.00
IRIX cash_flow (annual, 2023-12-31) — Provisionand Write Offof Assets: 0.00
IRIX cash_flow (annual, 2023-12-31) — Purchase Of PPE: -109000.00
IRIX balance_sheet (annual, 2023-12-31) — Raw Materials: 5288000.00
IRIX balance_sheet (annual, 2023-12-31) — Receivables: 9654000.00
IRIX income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 30062000.00
IRIX income_statement (annual, 2023-12-31) — Reconciled Depreciation: 2032000.00
IRIX cash_flow (annual, 2023-12-31) — Repayment Of Debt: 0.00
IRIX income_statement (annual, 2023-12-31) — Research And Development: 6829000.00
IRIX balance_sheet (annual, 2023-12-31) — Retained Earnings: -79042000.00
IRIX income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 16237000.00
IRIX income_statement (annual, 2023-12-31) — Selling General And Administration: 24985000.00
IRIX balance_sheet (annual, 2023-12-31) — Share Issued: 16252813.00
IRIX cash_flow (annual, 2023-12-31) — Stock Based Compensation: 1650000.00
IRIX balance_sheet (annual, 2023-12-31) — Stockholders Equity: 9522000.00
IRIX balance_sheet (annual, 2023-12-31) — Tangible Book Value: 6915000.00
IRIX income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
IRIX income_statement (annual, 2023-12-31) — Tax Provision: 90000.00
IRIX income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.21
IRIX balance_sheet (annual, 2023-12-31) — Total Assets: 34436000.00
IRIX balance_sheet (annual, 2023-12-31) — Total Capitalization: 9522000.00
IRIX balance_sheet (annual, 2023-12-31) — Total Debt: 2746000.00
IRIX balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 9522000.00
IRIX income_statement (annual, 2023-12-31) — Total Expenses: 61876000.00
IRIX balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 24914000.00
IRIX balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 6986000.00
IRIX balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 11940000.00
IRIX income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -10007000.00
IRIX balance_sheet (annual, 2023-12-31) — Total Tax Payable: 100000.00
IRIX balance_sheet (annual, 2023-12-31) — Work In Process: 156000.00
IRIX balance_sheet (annual, 2023-12-31) — Working Capital: 14476000.00
IRIX balance_sheet (quarterly, 2024-09-30) — Current Debt: 1314000.00
IRIX cash_flow (quarterly, 2024-09-30) — Issuance Of Debt: 3370000.00
IRIX cash_flow (quarterly, 2024-09-30) — Long Term Debt Issuance: 3370000.00
IRIX balance_sheet (quarterly, 2024-09-30) — Other Current Borrowings: 1314000.00
IRIX balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 1579000.00
IRIX cash_flow (quarterly, 2024-09-30) — Proceeds From Stock Option Exercised: 4000.00
IRIX balance_sheet (quarterly, 2024-09-30) — Work In Process: 15000.00
IRIX income_statement (annual, 2024-12-31) — +Operating Expense: 27804000.00
IRIX income_statement (annual, 2024-12-31) — +Total Revenue: 48669000.00
IRIX balance_sheet (annual, 2024-12-31) — Accounts Payable: 6985000.00
IRIX balance_sheet (annual, 2024-12-31) — Accounts Receivable: 5951000.00
IRIX balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -13983000.00
IRIX balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -13983000.00
IRIX balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 89881000.00
IRIX balance_sheet (annual, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -259000.00
IRIX cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 0.00
IRIX income_statement (annual, 2024-12-31) — Basic Average Shares: 16439000.00
IRIX income_statement (annual, 2024-12-31) — Basic EPS: -0.54
IRIX cash_flow (annual, 2024-12-31) — Beginning Cash Position: 7034000.00
IRIX cash_flow (annual, 2024-12-31) — Capital Expenditure: -13000.00
IRIX balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 1905000.00
IRIX balance_sheet (annual, 2024-12-31) — Capital Stock: 174000.00
IRIX balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 2387000.00
IRIX balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 2387000.00
IRIX cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 2605000.00
IRIX cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -13000.00
IRIX cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -7285000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Account Payable: 2486000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Accrued Expense: -1466000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Inventory: -911000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Other Current Assets: 2000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: -111000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Other Working Capital: -1903000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Payable: 2867000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 1401000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: -1108000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Receivables: 1260000.00
IRIX cash_flow (annual, 2024-12-31) — Change In Working Capital: -1370000.00
IRIX cash_flow (annual, 2024-12-31) — Changes In Account Receivables: 776000.00
IRIX cash_flow (annual, 2024-12-31) — Changes In Cash: -4693000.00
IRIX balance_sheet (annual, 2024-12-31) — Common Stock: 174000.00
IRIX balance_sheet (annual, 2024-12-31) — Common Stock Equity: 2097000.00
IRIX cash_flow (annual, 2024-12-31) — Common Stock Issuance: 3370000.00
IRIX cash_flow (quarterly, 2024-12-31) — Common Stock Issuance: 0.00
IRIX income_statement (annual, 2024-12-31) — Cost Of Revenue: 29167000.00
IRIX balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 770000.00
IRIX balance_sheet (annual, 2024-12-31) — Current Assets: 23562000.00
IRIX balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 1094000.00
IRIX balance_sheet (annual, 2024-12-31) — Current Debt: 1734000.00
IRIX balance_sheet (quarterly, 2024-12-31) — Current Debt: 1734000.00
IRIX balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 2828000.00
IRIX balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 3488000.00
IRIX balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 3488000.00
IRIX balance_sheet (annual, 2024-12-31) — Current Liabilities: 16559000.00
IRIX cash_flow (annual, 2024-12-31) — Depreciation: 1424000.00
IRIX cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 1424000.00
IRIX cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 1424000.00
IRIX income_statement (annual, 2024-12-31) — Diluted Average Shares: 16439000.00
IRIX income_statement (annual, 2024-12-31) — Diluted EPS: -0.54
IRIX income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -8910000.00
IRIX balance_sheet (annual, 2024-12-31) — Duefrom Related Parties Current: 2443000.00
IRIX balance_sheet (annual, 2024-12-31) — Dueto Related Parties Current: 609000.00
IRIX income_statement (annual, 2024-12-31) — EBIT: -8302000.00
IRIX income_statement (annual, 2024-12-31) — EBITDA: -6878000.00
IRIX cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 46000.00
IRIX cash_flow (annual, 2024-12-31) — End Cash Position: 2387000.00
IRIX cash_flow (annual, 2024-12-31) — Financing Cash Flow: 2605000.00
IRIX balance_sheet (annual, 2024-12-31) — Finished Goods: 6581000.00
IRIX cash_flow (annual, 2024-12-31) — Free Cash Flow: -7298000.00
IRIX balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 51000.00
IRIX income_statement (annual, 2024-12-31) — General And Administrative Expense: 9776000.00
IRIX balance_sheet (annual, 2024-12-31) — Goodwill: 965000.00
IRIX balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 2271000.00
IRIX balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 6210000.00
IRIX balance_sheet (annual, 2024-12-31) — Gross PPE: 15890000.00
IRIX income_statement (annual, 2024-12-31) — Gross Profit: 19502000.00
IRIX cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 15000.00
IRIX cash_flow (quarterly, 2024-12-31) — Income Tax Paid Supplemental Data: -2000.00
IRIX balance_sheet (annual, 2024-12-31) — Inventory: 10817000.00
IRIX balance_sheet (annual, 2024-12-31) — Invested Capital: 4835000.00
IRIX cash_flow (annual, 2024-12-31) — Investing Cash Flow: -13000.00
IRIX cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 3370000.00
IRIX balance_sheet (annual, 2024-12-31) — Leases: 2494000.00
IRIX balance_sheet (quarterly, 2024-12-31) — Leases: 2494000.00
IRIX balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 811000.00